Comparison of different forms of tranexamic acid in the treatment of hemoptysis

Comparison of nebulized and parenteral forms of tranexamic acid (at different doses) in treatment of mild to moderate hemoptysis.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211026052880N1

Enrollment

120

Registered

2025-08-18

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoptysis. Hemoptysis

Interventions

Intervention 1: First intervention group: People with mild to moderate hemoptysis in the tranexamic acid nebulizer group. Intervention 2: Second intervention group: People with mild to moderate hemopt

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: All patients with mild to moderate hemoptysis 18 to 75 years old

Exclusion criteria

Exclusion criteria: Unwillingness to cooperation unstable/life-threatening clinical conditions life-threatening hemoptysis drug intolerance development of any allergic conditions to the drug contraindication to tranexamic acid

Design outcomes

Primary

Measure	Time frame
Measuring the amount of hemoptysis based on the cc of blood excreted after the start of treatment based on the drug type. Timepoint: After receiving the drug, patients are evaluated for bleeding volume at 30 minutes, 6 hours, 12 hours, 24 hours, 48 hours and 72 hours after starting treatment with different forms of tranexamic acid, according to the assigned group (A/B/C). Bleeding volume will be categorized based on the presence of blood streaks (mild), less than 100 CC (moderate), and more than 100 CC (severe).The comparison of bleeding cessation time between different groups will also be evaluated. Method of measurement: Measuring with a graduated container.	—

Measure

Time frame

Measuring the amount of hemoptysis based on the cc of blood excreted after the start of treatment based on the drug type. Timepoint: After receiving the drug, patients are evaluated for bleeding volume at 30 minutes, 6 hours, 12 hours, 24 hours, 48 hours and 72 hours after starting treatment with different forms of tranexamic acid, according to the assigned group (A/B/C). Bleeding volume will be categorized based on the presence of blood streaks (mild), less than 100 CC (moderate), and more than 100 CC (severe).The comparison of bleeding cessation time between different groups will also be evaluated. Method of measurement: Measuring with a graduated container.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHale Afshar

Iran University of Medical Sciences

afshar.hale@gmail.com+98 21 6435 2486

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026